Quick Answer
aTYR PHARMA INC reported Research And Development Expense of $60.22 million for the year ending 2025.
- aTYR PHARMA INC showed an increase of +10.8% in Research And Development Expense from 2024 to 2025.
- This data is from aTYR PHARMA INC's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $4.39 million | Q2 2014: $3.64 million | Q3 2014: $4.41 million | Q1 2015: $6.59 million | Q2 2015: $7.50 million | Q3 2015: $7.74 million | Q1 2016: $12.00 million | Q2 2016: $11.31 million | Q3 2016: $10.40 million | Q1 2017: $9.20 million | Q2 2017: $8.42 million | Q3 2017: $7.13 million | Q1 2018: $6.15 million | Q2 2018: $6.48 million | Q3 2018: $4.20 million | Q1 2019: $3.35 million | Q2 2019: $3.31 million | Q3 2019: $3.80 million | Q1 2020: $3.62 million | Q2 2020: $4.36 million | Q3 2020: $4.62 million | Q1 2021: $4.52 million | Q2 2021: $7.66 million | Q3 2021: $5.14 million | Q1 2022: $8.90 million | Q2 2022: $9.14 million | Q3 2022: $9.87 million | Q1 2023: $9.38 million | Q2 2023: $9.84 million | Q3 2023: $10.32 million | Q1 2024: $13.36 million | Q2 2024: $13.97 million | Q3 2024: $14.81 million | Q1 2025: $11.81 million | Q2 2025: $15.38 million | Q3 2025: $22.13 million.
- Over the full 13 years of available data (2013 to 2025), aTYR PHARMA INC's Research And Development Expense has grown by 335.4%.
- Historical annual values: Fiscal year 2025: $60.22 million | Fiscal year 2024: $54.37 million | Fiscal year 2023: $42.29 million | Fiscal year 2022: $42.81 million | Fiscal year 2021: $23.26 million | Fiscal year 2020: $17.29 million | Fiscal year 2019: $14.05 million | Fiscal year 2018: $20.39 million | Fiscal year 2017: $30.07 million | Fiscal year 2016: $42.85 million | Fiscal year 2015: $34.50 million | Fiscal year 2014: $16.78 million | Fiscal year 2013: $13.83 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: